Group 1 - The core viewpoint of the articles emphasizes the chronic nature of asthma as an airway inflammatory disease that requires ongoing management and treatment to prevent acute attacks and long-term complications [2][4][6] - The importance of adhering to prescribed inhalation therapies, particularly the combination of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA), is highlighted as essential for controlling inflammation and alleviating symptoms [3][4] - A significant portion of asthma patients in China, approximately 55%-70%, are not effectively managing their condition, indicating a substantial unmet medical need [3] Group 2 - Severe asthma patients, constituting about 5% of the asthma population in China, face higher risks of complications and economic burdens due to frequent acute episodes and hospitalizations [5] - Innovative therapies, particularly biologics, are emerging as effective treatments for severe asthma, targeting specific inflammatory pathways and reducing reliance on corticosteroids [5][6] - The recent update to the bronchial asthma prevention and treatment guidelines introduces the concept of "clinical cure," offering hope for better management and quality of life for severe asthma patients [6]